30 results about "VENTRICULAR RHYTHMS" patented technology

A cardiac rhythm management device which employs pacing therapy to regularize the ventricular rhythm. Such ventricular rate regularization may be employed within bradycardia pacemakers, ventricular resynchronization devices, or implantable cardioverter / defibrillators.

A system (10) for achieving a desired cardiac rate and cardiac rhythm in response to atrial fibrillation in a heart includes an atrial fibrillation (AF) detector (40) for detecting AF. The system also includes an atrioventricular node vagal stimulator (AVN-VS) (30) for stimulating vagal nerves associated with an atrioventricular (AV) node of the heart. The system further includes an on-demand pace maker (40) for providing ventricular pacing stimulation to the heart. A control unit (20) is operatively connected with the AF detection device, the AVN-VS device, and the on-demand pacing device. The control unit is responsive to AF detection by the AF detector to cause the AVN-VS to stimulate the vagal nerves to help reduce the ventricular rate of the heart. The control unit is further responsive to AF detection by the AF detector to cause the on-demand pace maker to help regulate the ventricular rate of the heart.

A device is connected to electrode leads which performs intracardiac impedance measurements, conducts a transient pacing protocol, analyses the impedance measurements, and generates an LV lead position quality factor. The transient pacing protocol includes a repeated change (“transitions”) between ventricular intrinsic rhythm and biventricular paced rhythm and may also include a variation of the atrioventricular delay (AVD) and / or the interventricular delay (VVD). The quality factor expresses the degree to which hemodynamic properties have improved due to BiV stimulation for the current LV lead position compared to intrinsic ventricular rhythm.

The invention relates to a brominated crebanine compound and preparation method and an application thereof, which belongs to the technical field of medicine. The invention firstly discloses the synthesis of 3-brominated crebanine and 10, 11-brominated crebanine, through research on effect of chloroform for inducing mice arrhythmia, the research shows that the 3-brominated crebanine and 10, 11-brominated crebanine can antagonize the chloroform-induced ventricular fibrillation, so that the 3-brominated crebanine and 10, 11-brominated crebanine have anti-arrhythmia effect through preliminary determination; the barium chloride-induced rat ventricular rhythm tests confirm that the 3-brominated crebanine and 10, 11-brominated crebanine have good anti-arrhythmia effect, acute toxicity of two brominated crebanine compounds is lower than that of crebanine, LD50 is 65.15+ / -1.132 mg / kg of 3-brominated crebanine and 59.62+ / -2.610 mg / kg of 10,11-brominated crebanine respectively, and a good base can be established for further deep researches.

A cardiac rhythm management device which employs pacing therapy to regularize the ventricular rhythm. Such ventricular rate regularization may be employed within bradycardia pacemakers, ventricular resynchronization devices, or implantable cardioverter / defibrillators.

An implantable medical device is provided for detecting transportless ventricular rhythm of a heart lacking atrial transport and comprises a housing, sensors configured to be located proximate to a heart, a sensing module to sense cardiac signals representative of a rhythm originating from the heart and a rhythm detection module. The rhythm detection module determines a change in AV association and identifies a potential ventricular complex with loss of atrial transport (VCLAT) based on the change in AV association.

An implantable cardiac system that includes an implantable cardiac pacemaker or leadless pacemaker (iLP) and a second device such as a subcutaneous implantable cardioverter-defibrillator (S-ICD). The pacemaker includes an R-spike amplifier that amplifies stimulated ventricle excitations or R-waves to increase R-wave to T-wave signal to noise ratio and to improve indirect detection of ventricular rhythm classification by the S-ICD. The S-ICD includes an electrode line for defibrillation, a sensing unit and a stimulation detection unit. The S-ICD records a subcutaneous electrocardiogram between shock electrode poles and provides potentially life-saving therapy based thereon. The system significantly increases the specificity and sensitivity of an S-ICD in combination with an implanted cardiac pacemaker or iLP having an R-spike amplifier.

The present invention provides a cardiac pace making system. The cardiac pace making system comprises a sensing module, a pace making module, and a control module. Under a normal atria ventricular conduction condition, the control module controls the cardiac pace making system to work in a first mode and detect whether an atria ventricular block has occurred; various atria ventricular block events are determined accurately by sensing and comparing PR intervals and missed ventricular events; when an atria ventricular block occurs, the control module controls the cardiac pace making system to work in a second mode, so that a cardiac pacemaker may work in a timely manner and in an appropriate mode and provide an appropriate AV time sequence and ventricular rhythm.

The invention discloses a device for discriminating malignant ventricular arrhythmia. After the sampling module discretely samples the continuous ECG signal; the amplitude-frequency characteristic extraction module extracts the amplitude-frequency characteristic of the signal and obtains a matrix; then the frequency band selection module Select the vector of the preset frequency band from the matrix to obtain a new matrix; then the feature extraction module will select the column vector of the preset number with the largest variance from the new matrix as the feature vector of the signal; the classification module will then The feature vector is input into a pre-trained classifier to obtain a classification result; finally, the discrimination module judges whether the electrocardiographic signal is a malignant ventricular rhythm according to the classification result. It can be seen that the device can select a preset number of vectors with the largest variance from the vectors of the preset frequency band as feature vectors, which effectively reduces the amount of calculation of the classifier and saves the time spent on discrimination. The present invention also provides a device for judging malignant ventricular rhythm, the function of which is corresponding to that of the above-mentioned device.

An implantable cardiac stimulator includes a cardioversion / defibrillation unit connected to at least one electrode pair for generation and delivery of cardioversion or defibrillation shocks; an atrial sensing unit detecting atrial contraction, and outputting an atrial sensing signal indicating a atrial event when an atrial contraction is detected; a ventricular sensing unit detecting ventricular contraction, and outputting a ventricular sensing signal when a ventricular contraction is detected; a tachycardia detection unit connected to the atrial and ventricular sensing units and detecting a tachycardia, and classifying it as a ventricular tachycardia (VT) or as a supraventricular tachycardia (SVT); and a treatment control unit designed to trigger at least one atrial cardioversion shock when a ventricular rhythm detected by the ventricular sensing unit is faster than a programmed frequency limit, and the tachycardia detection unit classifies an SVT as an atrial fibrillation (AFib).